MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at a Drug Information Association (DIA) workshop on using patient adherence data at the University of California Washington Center in Washington, DC. Dr. Poland will present on May 6, 2008, joining other leading experts from the pharmaceutical industry and academia in a session on the utility of incorporating adherence estimates in the design of clinical trials intended to learn about exposure-response relationships.
The workshop will provide a forum for scientific discussion and collaborative exchange on opportunities for the use of new methods in the conduct and interpretation of clinical trials through the use of reliable patient adherence data. Dr. Poland's presentation, entitled "Incorporating Adherence into Antiviral Clinical Trial Predictions", will describe how quantitative models of patient compliance for new antiviral agents can be linked with predictive drug-disease models to optimize dosing strategies and support clinical trial simulations. Further information can be found at http://www.diahome.org.
"Antiviral drugs present special therapeutic challenges to development teams, including patient compliance with long-term treatment regimens," said Shawn O'Connor, president, CEO and chairman of Pharsight. "To support planning and quantitative decision-making for antiviral development, it is important to account for highly variable patient compliance in the complexities of viral dynamics modeling. Model-based approaches can lead to enhanced clinical trial designs and in developing strategies to optimize tradeoffs such as that between patient compliance and dosing regimen, as well as inform better clinical program investment decisions. Pharsight is pleased to present at this important adherence workshop and to continue its contributions at DIA events, where we look forward to sharing our experience with industry colleagues and interacting with fellow practitioners of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.
SOURCE Pharsight Corporation